Damian Garde, Ed Silverman / STAT
Link to story
Discussion
We’re in this colossal economic and health mess precisely because we did not offer generous incentives to make treatments or vaccines for pandemics— and so lets not create artificial and ruinous concepts like “healthcare budgets” https://t.co/IapRwywnmC
— Amitabh Chandra (@amitabhchandra2) May 15, 2020
As @snlester and @mercuriobryan have pointed out, there is a need to make sure we don't kill the goose that lays the eggs. While the public sector is absolutely essential in research for any epidemic, the private sector also has a critical role. — 1/3 https://t.co/xCSqUm21OO
— Aidan Hollis (@aidanhollis) May 16, 2020
It was great to talk with @statnews about pricing for covid-19 treatments.
— Craig Garthwaite (@C_Garthwaite) May 15, 2020
As we think about how to price in a pandemic, we can't forget the role of incentives.
It'd be a different conversation if we believed remdesivir were the last treatment we needed, but it's not (1/4) https://t.co/I8LOqtgoG7
Hate that I’m saying this out loud but @C_Garthwaite is 100% right
— Zack Cooper (@zackcooperYale) May 15, 2020
Between now and when a vaccine comes out, an effective treatment to COVID is, in part, what will kickstart the economy
The social value to progress is potentially worth trillions for a good treatment. https://t.co/UGURlZzBee
Interesting piece illustrating global pricing debates, but overlooks two critical issues: 1) not all countries should/will pay same price; value/affordability different; 2) price ultimately determined by payers' willingness to pay, not abstract principles https://t.co/z8ofFaH9uY
— Rachel Silverman (@rsilv_dc) May 15, 2020
My contribution was just to ask what 'affordability' means to patients when the drug is given in the hospital (versus picked up from pharmacy).
— Walid Gellad, MD MPH (@walidgellad) May 15, 2020
Most patients won't pay extra to receive remdesivir. https://t.co/8l7bsHVEz1
